|
US2021032322A1
|
|
Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor
|
|
WO2020257640A1
|
|
Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
|
|
US2020317788A1
|
|
Semaphorin-4d antagonists for use in cancer therapy
|
|
BR112019023138A2
|
|
4d human anti-semaphorin antibody
|
|
AU2018237549A1
|
|
Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent
|
|
WO2018156509A1
|
|
Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
|
|
MX2019001453A
|
|
Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells.
|
|
KR20180135483A
|
|
Intrinsic membrane protein display in the poxvirus extracellular coat-type virion
|
|
NZ630881A
|
|
Use of semaphorin-4d binding molecules for treatment of atherosclerosis
|
|
NZ630892A
|
|
Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
|
|
KR20160024391A
|
|
Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
|
|
CN105339379A
|
|
Modified glycolipids and methods of making and using the same
|
|
WO2014121053A1
|
|
Methods for increasing immunoglobulin a levels
|
|
US2013302320A1
|
|
Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
|
|
US2013288927A1
|
|
Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
|
|
US2014099334A1
|
|
Anti-SEMA4D antibodies and epitopes
|
|
US2014227296A1
|
|
Modified glycolipids and methods of making and using the same
|
|
AU2013205589A1
|
|
Anti-CXCL13 antibodies and associated epitope sequences
|
|
AU2013225812A1
|
|
Methods for the treatment of B cell-mediated inflammatory diseases
|
|
US2013142810A1
|
|
Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
|
